Skip to main content
PMC home page
PLOS Medicine logoLink to PLOS Medicine
. 2020 Sep 8;17(9):e1003308. doi: 10.1371/journal.pmed.1003308

Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study

Lars Christian Lund 1,#, Kasper Bruun Kristensen 1,#, Mette Reilev 1, Steffen Christensen 2, Reimar Wernich Thomsen 3, Christian Fynbo Christiansen 3, Henrik Støvring 1,4, Nanna Borup Johansen 5, Nikolai Constantin Brun 5, Jesper Hallas 1, Anton Pottegård 1,*
Editor: Anne C Cunningham6
PMCID: PMC7478808  PMID: 32898149

Abstract

Background

Concerns over the safety of non-steroidal anti-inflammatory drug (NSAID) use during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been raised. We studied whether use of NSAIDs was associated with adverse outcomes and mortality during SARS-CoV-2 infection.

Methods and findings

We conducted a population-based cohort study using Danish administrative and health registries. We included individuals who tested positive for SARS-CoV-2 during the period 27 February 2020 to 29 April 2020. NSAID users (defined as individuals having filled a prescription for NSAIDs up to 30 days before the SARS-CoV-2 test) were matched to up to 4 non-users on calendar week of the test date and propensity scores based on age, sex, relevant comorbidities, and use of selected prescription drugs. The main outcome was 30-day mortality, and NSAID users were compared to non-users using risk ratios (RRs) and risk differences (RDs). Secondary outcomes included hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and acute renal replacement therapy. A total of 9,236 SARS-CoV-2 PCR-positive individuals were eligible for inclusion. The median age in the study cohort was 50 years, and 58% were female. Of these, 248 (2.7%) had filled a prescription for NSAIDs, and 535 (5.8%) died within 30 days. In the matched analyses, treatment with NSAIDs was not associated with 30-day mortality (RR 1.02, 95% CI 0.57 to 1.82, p = 0.95; RD 0.1%, 95% CI −3.5% to 3.7%, p = 0.95), risk of hospitalization (RR 1.16, 95% CI 0.87 to 1.53, p = 0.31; RD 3.3%, 95% CI −3.4% to 10%, p = 0.33), ICU admission (RR 1.04, 95% CI 0.54 to 2.02, p = 0.90; RD 0.2%, 95% CI −3.0% to 3.4%, p = 0.90), mechanical ventilation (RR 1.14, 95% CI 0.56 to 2.30, p = 0.72; RD 0.5%, 95% CI −2.5% to 3.6%, p = 0.73), or renal replacement therapy (RR 0.86, 95% CI 0.24 to 3.09, p = 0.81; RD −0.2%, 95% CI −2.0% to 1.6%, p = 0.81). The main limitations of the study are possible exposure misclassification, as not all individuals who fill an NSAID prescription use the drug continuously, and possible residual confounding by indication, as NSAIDs may generally be prescribed to healthier individuals due to their side effects, but on the other hand may also be prescribed for early symptoms of severe COVID-19.

Conclusions

Use of NSAIDs was not associated with 30-day mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in Danish individuals who tested positive for SARS-CoV-2.

Trial registration

The European Union electronic Register of Post-Authorisation Studies EUPAS34734

In a nationwide cohort study, Lars C. Lund, Kasper B. Kristensen, and colleagues investigate the association of NSAID use and outcomes in COVID-19 patients.

Author summary

Why was this study done?

  • During the early phases of the pandemic of coronavirus disease 2019 (COVID-19), concerns were raised that ibuprofen, a drug commonly used to treat weak pain and fevers, may lead to a more severe course of coronavirus disease.

  • If this risk is verified, it would be important to reduce the use of ibuprofen and ibuprofen-like drugs, commonly referred to as non-steroidal anti-inflammatory drugs (NSAIDs), among patients at risk of COVID-19.

What did the researchers do and find?

  • We identified all Danish residents who tested positive for the infectious agent of COVID-19 and grouped them into users and non-users of NSAIDs.

  • The risks of being hospitalized, admitted to the intensive care unit, or dying were compared between the 2 groups.

  • Overall, risks for all studied outcomes were similar between users and non-users of ibuprofen and other NSAIDs.

What do these findings mean?

  • NSAIDs do not lead to more severe coronavirus disease according to this study.

Introduction

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to transmit and spread in Europe and the United States, a letter suggesting that ibuprofen could influence the prognosis of coronavirus disease 2019 (COVID-19) through upregulation of angiotensin converting enzyme 2 receptors was circulated widely [1]. Because of this letter and case reports of otherwise healthy young patients with severe COVID-19 who had used NSAIDs in the early stage of disease [2], concerns regarding the safety of NSAID use during the COVID-19 pandemic were widely circulated, including warnings against NSAID use in COVID-19 from the French health minister [2] and the World Health Organization. However, the European Medicines Agency stated that evidence to support warnings against use of NSAIDs in COVID-19 was lacking and stressed the need for further evidence on any effects of NSAIDs on disease prognosis in COVID-19 [3].

The available evidence stems mainly from studies on community-acquired bacterial pneumonia and shows that use of NSAIDs is associated with bacterial complications, specifically empyema and lung abscesses [4–7]. For viral illness, use of NSAIDs was not associated with mortality in intensive care unit (ICU) patients with influenza H1N1 during the 2009 pandemic [8], and a recent study found that use of NSAIDs was not associated with mortality in patients hospitalized for influenza [9]. As use of ibuprofen and other NSAIDs is widespread, data on their safety are urgently needed to guide clinicians and patients on how to use NSAIDs during the COVID-19 pandemic. We therefore examined whether use of NSAIDs prior to infection with SARS-CoV-2 was associated with increased risk of hospitalization, ICU admission, and mortality compared to non-use of NSAIDs.

Methods

We conducted a Danish nationwide registry-based cohort study investigating the association between NSAID use and 30-day mortality and other adverse outcomes, specified as hospitalization, ICU admission, mechanical ventilation, and acute renal replacement therapy, in all patients who tested positive for SARS-CoV-2. For a graphical representation of the study design, see Fig 1. All analyses followed the publicly registered protocol [10], except for a change in the matching algorithm and a post hoc analysis of test-negative individuals (both detailed below). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 STROBE Checklist). The institutional data protection board at the University of Southern Denmark and the Danish Health Data Authority approved the research project. According to Danish law, studies based entirely on registry data do not require approval from an ethics review board [11]. All source code used to conduct this study is freely available at https://source.coderefinery.org/lcl/nsaid-covid19.

Fig 1. Study design diagram.

Fig 1

Open in a new tab

NSAID, non-steroidal anti-inflammatory drug; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Data sources

Data on all Danish residents with a positive test for SARS-CoV-2 were obtained from Danish health and administrative registries as described elsewhere [12]. In brief, identification of the study population was based on prospectively collected data on all Danish residents receiving a polymerase chain reaction (PCR) test for SARS-CoV-2 from the Danish Microbiology Database [13]. Data were linked to the Danish Civil Registration System [14], the Danish National Prescription Registry [15], the Danish National Patient Registry [16], and the Danish Register of Causes of Death [17] by means of the unique personal identifier assigned to all Danish residents at birth or immigration. Data on ICU treatment, mechanical ventilation, and renal replacement therapy from the Danish National Patient Registry were supplemented with daily reports on admitted patients from the 5 Danish regions [16,18]. For more details regarding individual registries, see S1 Appendix.

Study population

All Danish residents who had a positive PCR test for SARS-CoV-2 during the period 27 February 2020 to 29 April 2020 were included in the study. To ensure complete information on exposure and covariates prior to cohort entry, individuals with less than 1 year of residence in Denmark prior to the positive test for SARS-CoV-2 were excluded. For all secondary outcomes, individuals with an outcome during 30 days to 1 day prior to cohort entry were excluded, partly to ensure that outcomes were incident and plausibly occurring due to COVID-19 and partly because in-hospital drug use was not available from the Danish National Prescription Registry.

We conducted a post hoc supplementary analysis where we examined the same association in a cohort of all Danish patients who tested negative for SARS-CoV-2 in the study period.

Exposure

The exposure of interest was current use of any NSAID prior to a positive SARS-CoV-2 test. Current use was defined as having filled a prescription for any NSAID in the 30 days prior to the positive test. Filled NSAID prescriptions were identified from the Danish National Prescription Registry, with information on all dispensed prescriptions at community pharmacies in Denmark since 1995 [19]. Users of NSAIDs were compared to individuals without NSAID use in the corresponding time window. In Denmark, NSAIDs are sold by prescription except for low-dose (200 mg) ibuprofen sold over-the-counter in pack sizes of no more than 20 tablets. In 2018, over-the-counter purchases of ibuprofen constituted 15% of total ibuprofen sales and a smaller proportion of total NSAID sales [20]. Hence, the potential to identify NSAID use from the Danish National Prescription Registry is high compared to many other countries where over-the-counter use of NSAIDs is common [19,21].

Outcomes

The main outcome of interest was death within 30 days of a positive test for SARS-CoV-2.

The secondary outcomes included hospitalization, ICU admission, mechanical ventilation, and acute renal replacement therapy within 14 days of a positive test for SARS-CoV-2.

Follow-up

Eligible individuals were followed until the end of follow up (30 days for the main outcome, 14 days for secondary outcomes) or the event of interest.

Propensity score matching

We used propensity score (PS) matching to increase comparability between NSAID users and non-users. The PS is the estimated probability of receiving the treatment of interest given a set of characteristics [22]. PSs were estimated on the day of the positive SARS-CoV-2 test using logistic regression. Independent variables in the PS model were age, sex, relevant comorbidities, use of selected prescription drugs, and phase of the outbreak. For details of these independent variables, see S2 Appendix. A separate PS was estimated for each exposure definition in the main and supplementary analyses. To evaluate the appropriateness of the model, PS distributions were plotted separately for each cohort and overlap assessed visually. To reduce unmeasured confounding, individuals in the tails of the PS distribution were trimmed asymmetrically [23]. Up to 4 non-users were matched to each NSAID user using a nearest neighbor algorithm. Non-users could be matched to multiple NSAID users, and the maximum allowed difference in the PS between matches was 0.05 [24]. The Danish SARS-CoV-2 test strategy was subject to marked changes from a limited capacity setting in the beginning of the study period to a setting where widespread testing was available at the end of the study period. To account for this [25], we included calendar week of the test date as a forced matching variable. This decision was made post hoc, i.e., not included in the protocol. Covariate balance before and after matching was assessed using standardized mean differences [26].

Statistical analyses

Descriptive statistics were used to describe NSAID users and non-users at baseline. Continuous variables were reported as medians and interquartile ranges. Dichotomous variables were reported as frequencies and percentages.

Risks and risk differences (RDs) were estimated using generalized linear models with a binomial distribution and an identity link. Risk ratios (RRs) were estimated similarly but using a log link. Matched analyses were implemented using frequency weighting, i.e., NSAID users were assigned a weight of 1, and non-users’ weights were assigned according to each individual user’s number of matches. Robust 95% confidence intervals were calculated using the sandwich estimator of variance where the assumption regarding independence of observations was relaxed in the matched analyses. Data management and statistical analyses were performed using Stata 16 MP. The codes used to define exposures, covariates, and outcomes are available in S2 Appendix.

Subgroup analyses

To explore treatment effect heterogeneity, we repeated the main analyses stratifying by age (<65 years, 65+ years), sex, and history of cardiovascular disease. To examine whether widespread testing of healthcare workers influenced the findings, we repeated the main analyses excluding healthcare workers from the study population. We used the same PS as estimated in the main analyses for the subgroup analyses [27].

Supplementary analyses

We conducted the following supplementary analyses. (1) We relaxed the exposure definition by using an extended NSAID exposure assessment window of 60 days prior to the positive test and repeated the main analyses with this exposure definition. (2) To explore whether reverse causation may have influenced the findings, effect estimates were obtained using an exposure assessment window of 60 days to 14 days before cohort entry (i.e., disregarding NSAID prescriptions filled during the 14 days immediately prior to cohort entry). (3) To evaluate the robustness of the findings with regards to the chosen outcome assessment windows, we obtained 60-day risk estimates for mortality and 30-day risk estimates for secondary outcomes. (4) To examine the potential for residual confounding, we conducted a negative control analysis by repeating the main analyses within the test-negative population, i.e. individuals who tested negative for SARS-CoV-2 (and did not later test positive). If an individual was tested more than once, the first test date was used as the cohort entry date. This post hoc analysis was not specified in the protocol.

Results

We identified 9,370 individuals who tested positive for SARS-CoV-2 during the study period. Of these, 134 were excluded due to migration within 1 year prior to cohort entry, resulting in an eligible population of 9,236 individuals followed for a total of 705 person-years. The median age in the study cohort was 50 years, and 58% were female. Overall, 535 individuals (5.8%) died within 30 days, 1,512 (16%) were hospitalized within 14 days, 290 (3.1%) were admitted to the ICU, 235 (2.5%) received mechanical ventilation, and 61 (0.7%) received acute renal replacement therapy. In total, 248 (2.7%) patients had filled a prescription for an NSAID within 30 days before the test date. Compared to non-users, NSAID users were older (median age 55 versus 49 years) and more likely to have a history of hospital-diagnosed overweight or obesity (13% versus 9%), to have medical indications for NSAID use such as osteoarthritis (19% versus 12%) or rheumatoid arthritis (7% versus 3%), and to have been prescribed opioids the year before sampling date (24% versus 11%). After matching, covariates were well balanced, with standardized mean differences ≤ 0.1 (Table 1). Use of opioids was strongly associated with use of NSAIDs and 30-day mortality, while cardiovascular disease and dementia was negatively associated with use of NSAIDs and positively associated with death (S1 Table).

Table 1. Baseline characteristics in the unmatched and propensity-score-matched cohorts.

 Characteristic Unmatched Matched
NSAID users
(n = 248)		 Non-users
(n = 8,988)		 SMD NSAID users
(n = 224)		 Non-users
(n = 896)		 SMD
Age in years, median (IQR) 55 (43–64) 49 (35–63) 0.24 54 (43–64) 54 (41–66) 0.00
Sex male 99 (39.9) 3,793 (42.2) 0.05 90 (40.2) 375 (41.9) 0.03
Prescription drugs*
Antihypertensive 72 (29.0) 2,221 (24.7) 0.10 62 (27.7) 233 (26.0) 0.04
Antidiabetic drug 26 (10.5) 680 (7.6) 0.10 21 (9.4) 78 (8.7) 0.02
Low-dose aspirin 16 (6.5) 532 (5.9) 0.02 15 (6.7) 47 (5.2) 0.06
Immunosuppressant (n < 5) 63 (0.7) 0.05 (n < 5) 6 (0.7) 0.07
Opioid 59 (23.8) 950 (10.6) 0.36 46 (20.5) 172 (19.2) 0.03
Z-drug 8 (3.2) 279 (3.1) 0.01 7 (3.1) 28 (3.1) 0.00
Benzodiazepine 10 (4.0) 378 (4.2) 0.01 10 (4.5) 38 (4.2) 0.01
First generation antipsychotic (n < 5) 58 (0.6) 0.03 (n < 5) (n < 5) 0.02
Second generation antipsychotic (n < 5) 224 (2.5) 0.10 (n < 5) 11 (1.2) 0.03
Systemic glucocorticoid 19 (7.7) 431 (4.8) 0.12 15 (6.7) 65 (7.3) 0.02
Inhaled corticosteroid 27 (10.9) 625 (7.0) 0.14 21 (9.4) 92 (10.3) 0.03
Prior diagnoses**
Asthma 16 (6.5) 613 (6.8) 0.01 13 (5.8) 47 (5.2) 0.02
COPD 11 (4.4) 368 (4.1) 0.02 9 (4.0) 35 (3.9) 0.01
Cardiovascular disease 28 (11.3) 1,238 (13.8) 0.08 23 (10.3) 91 (10.2) 0.00
Ischemic stroke 9 (3.6) 376 (4.2) 0.03 8 (3.6) 30 (3.3) 0.01
Chronic kidney failure (n < 5) 126 (1.4) 0.11 (n < 5) (n < 5) 0.06
Liver disease (n < 5) 125 (1.4) 0.02 (n < 5) 10 (1.1) 0.06
Alcohol-related disorders 5 (2.0) 239 (2.7) 0.04 (n < 5) 12 (1.3) 0.04
Dementia (n < 5) 154 (1.7) 0.08 (n < 5) 10 (1.1) 0.02
Cancer 21 (8.5) 646 (7.2) 0.05 16 (7.1) 64 (7.1) 0.00
Overweight or obesity 33 (13.3) 765 (8.5) 0.15 29 (12.9) 111 (12.4) 0.02
Hemiplegia and paraplegia (n < 5) 35 (0.4) 0.00 (n < 5) (n < 5) 0.02
Osteoarthritis 47 (19.0) 1,054 (11.7) 0.20 37 (16.5) 143 (16.0) 0.02
Rheumatoid arthritis 17 (6.9) 308 (3.4) 0.16 13 (5.8) 51 (5.7) 0.00
Dysmenorrhea 7 (2.8) 62 (0.7) 0.16 (n < 5) 8 (0.9) 0.00
Open in a new tab

Data are given as number (percent) unless otherwise indicated.

*Defined as 1 or more prescription fills during the period 365 days to 1 day prior to cohort entry.

**Defined as 1 or more discharge diagnoses assigned up to 1 day prior to cohort entry.

COPD, chronic obstructive pulmonary disease; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug; SMD, standardized mean difference.

Main outcomes

NSAID use was not associated with 30-day mortality in the crude (unmatched) analyses or adjusted (matched) analyses (Table 2). In the adjusted analyses, the 30-day mortality rate was 6.3% (95% CI 3.1% to 9.4%) in NSAID users and 6.1% (95% CI 4.4% to 7.8%) in non-users, corresponding to a RD of 0.1% (95% CI −3.5 to 3.7, p = 0.95) and a RR of 1.02 (95% CI 0.57 to 1.82, p = 0.95).

Table 2. Association between current NSAID use and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy in unmatched and propensity-score-matched cohorts.

Outcome NSAID users Non-users Comparison
Number of events/sample size Risk (%) (95% CI) Number of events/sample size Risk (%) (95% CI) Risk difference (%) (95% CI) p-Value Risk ratio (95% CI) p-Value
Unmatched cohort
Death 14/248 5.6 (2.8, 8.5) 521/8,988 5.8 (5.3, 6.3) −0.2 (−3.1, 2.8) 0.92 0.97 (0.58, 1.63) 0.92
Hospitalization* 56/228 24.6 (19.0, 30.2) 1,456/8,414 17.3 (16.5, 18.1) 7.3 (1.6, 12.9) 0.01 1.42 (1.13, 1.79) <0.01
ICU admission* 11/247 4.5 (1.9, 7.0) 279/8,956 3.1 (2.8, 3.5) 1.3 (−1.3, 3.9) 0.31 1.43 (0.79, 2.58) 0.23
Mechanical ventilation* 10/248 4.0 (1.6, 6.5) 225/8,970 2.5 (2.2, 2.8) 1.5 (−0.9, 4.0) 0.23 1.61 (0.86, 2.99) 0.13
Renal replacement therapy* n < 5/248 —** —** —** 0.6 (−0.8, 1.9) 0.42 1.87 (0.59, 5.94) 0.29
Matched cohort
Death 14/224 6.3 (3.1, 9.4) 55/896 6.1 (4.4, 7.8) 0.1 (−3.5, 3.7) 0.95 1.02 (0.57, 1.82) 0.95
Hospitalization* 50/204 24.5 (18.6, 30.4) 175/826 21.2 (18.1, 24.3) 3.3 (−3.4, 10.0) 0.33 1.16 (0.87, 1.53) 0.31
ICU admission* 11/223 4.9 (2.1, 7.8) 42/889 4.7 (3.2, 6.2) 0.2 (−3.0, 3.4) 0.90 1.04 (0.54, 2.02) 0.90
Mechanical ventilation* 10/224 4.5 (1.8, 7.2) 35/891 3.9 (2.5, 5.3) 0.5 (−2.5, 3.6) 0.73 1.14 (0.56, 2.30) 0.72
Renal replacement therapy* n < 5/224 —** —** —** −0.2 (−2.0, 1.6) 0.81 0.86 (0.24, 3.09) 0.81
Open in a new tab

NSAID use was defined as having an NSAID prescription filled within 30 days prior to the date of cohort entry.

*Patients with a secondary outcome occurring during the exclusion assessment window were excluded, resulting in exclusion of n = 594 patients for hospitalization, n = 33 for ICU admission, n = 18 for mechanical ventilation, and n = 6 for renal replacement therapy in unmatched cohorts, and n = 90, n = 8, n = 5, and n < 5, respectively, in matched cohorts.

**Censored to preserve anonymity for counts n < 5.

ICU, intensive care unit; NSAID, non-steroidal anti-inflammatory drug.

Secondary outcomes

In the crude analyses, use of NSAIDs was associated with an increased risk of hospitalization (RR 1.42, 95% CI 1.13 to 1.79, p < 0.01) but was not associated with an increased risk of ICU admission (RR 1.43, 95% CI 0.79 to 2.58, p = 0.23), mechanical ventilation (RR 1.61, 95% CI 0.86 to 2.99, p = 0.13), or renal replacement therapy (RR 1.87, 95% CI 0.59 to 5.94, p = 0.29) (Table 2). After adjustment, NSAID use was not associated with hospitalization (RR 1.16, 95% CI 0.87 to 1.53, p = 0.31), ICU admission (RR 1.04, 95% CI 0.54 to 2.02, p = 0.90), mechanical ventilation (RR 1.14, 95% CI 0.56 to 2.30, p = 0.72), or renal replacement therapy (RR 0.86, 95% CI 0.24 to 3.09, p = 0.81).

Subgroup analyses

The subgroup analyses were limited by low power and wide confidence intervals (Table 3). In individuals below 65 years of age, the adjusted RR for death associated with NSAID use was 3.76 (95% CI 0.53 to 26.6, p = 0.18). After adjustment, use of NSAIDs was associated with hospitalization in females (RR 1.55, 95% CI 1.03–2.34, p = 0.03) but not in males (RR 0.92, 95% CI 0.62 to 1.36, p = 0.67). Otherwise, the RRs were not modified by patient characteristics.

Table 3. Association between current NSAID use and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy in propensity-score-matched cohorts according to subgroups of interest.

Subgroup Outcome Risk (%) (95% CI) Comparison
NSAID users Non-users Risk difference (%) (95% CI) p-Value Risk ratio (95% CI) p-Value
Age < 65 years Death 1.2 (−0.4, 2.8) 0.3 (−0.1, 0.7) 0.8 (−0.8, 2.5) 0.31 3.76 (0.53, 26.56) 0.18
Hospitalization 16.3 (10.6, 21.9) 11.2 (8.5, 13.9) 5.1 (−1.2, 11.3) 0.11 1.45 (0.95, 2.22) 0.08
ICU admission 1.2 (−0.4, 2.8) 2.5 (1.1, 3.8) −1.3 (−3.4, 0.8) 0.22 0.47 (0.11, 2.07) 0.43
Mechanical ventilation 1.2 (−0.4, 2.8) 1.8 (0.7, 3.0) −0.7 (−2.7, 1.3) 0.50 0.63 (0.14, 2.87) 0.55
Renal replacement therapy 0.6 (−0.6, 1.7) 1.1 (0.1, 2.1) −0.5 (−2.0, 1.0) 0.52 0.54 (0.06, 4.67) 0.57
Age 65+ years Death 23.5 (11.8, 35.3) 21.6 (16.0, 27.3) 1.9 (−11.1, 14.9) 0.77 1.09 (0.62, 1.91) 0.77
Hospitalization 60.5 (44.8, 76.3) 54.2 (46.0, 62.3) 6.4 (−11.2, 23.9) 0.48 1.12 (0.83, 1.51) 0.47
ICU admission 18.0 (7.2, 28.8) 10.9 (6.6, 15.2) 7.1 (−4.4, 18.6) 0.22 1.65 (0.81, 3.37) 0.17
Mechanical ventilation 15.7 (5.6, 25.8) 9.5 (5.5, 13.6) 6.1 (−4.6, 16.9) 0.26 1.64 (0.76, 3.53) 0.20
Renal replacement therapy 3.9 (−1.5, 9.3) 2.9 (0.5, 5.2) 1.1 (−4.8, 6.9) 0.72 1.37 (0.28, 6.73) 0.70
Female Death 4.5 (1.0, 8.0) 4.8 (2.8, 6.8) −0.3 (−4.4, 3.7) 0.88 0.93 (0.38, 2.27) 0.88
Hospitalization 21.7 (14.6, 28.8) 14.0 (10.5, 17.4) 7.7 (−0.2, 15.6) 0.05 1.55 (1.03, 2.34) 0.03
ICU admission 1.5 (−0.6, 3.6) 1.3 (0.4, 2.3) 0.1 (−2.1, 2.4) 0.90 1.11 (0.23, 5.29) 0.90
Mechanical ventilation 1.5 (−0.6, 3.6) 0.6 (−0.1, 1.2) 0.9 (−1.2, 3.1) 0.41 2.59 (0.44, 15.36) 0.30
Renal replacement therapy — 0.8 (0.0, 1.5) — — — —
Male Death 8.9 (3.0, 14.8) 8.0 (5.1, 10.9) 0.9 (−5.7, 7.5) 0.79 1.11 (0.52, 2.37) 0.79
Hospitalization 29.3 (19.0, 39.7) 31.9 (26.3, 37.5) −2.6 (−14.3, 9.2) 0.67 0.92 (0.62, 1.36) 0.67
ICU admission 10.1 (3.8, 16.4) 9.5 (6.2, 12.8) 0.6 (−6.5, 7.7) 0.86 1.07 (0.52, 2.17) 0.86
Mechanical ventilation 8.9 (3.0, 14.8) 8.6 (5.4, 11.8) 0.3 (−6.4, 7.0) 0.94 1.03 (0.48, 2.20) 0.94
Renal replacement therapy 3.3 (−0.4, 7.1) 2.7 (0.6, 4.7) 0.7 (−3.6, 4.9) 0.76 1.25 (0.32, 4.83) 0.75
No history of cardiovascular disease Death 4.5 (1.6, 7.3) 3.5 (2.2, 4.8) 1.0 (−2.1, 4.1) 0.53 1.29 (0.62, 2.69) 0.50
Hospitalization 23.9 (17.8, 30.1) 19.3 (16.2, 22.5) 4.6 (−2.3, 11.5) 0.19 1.24 (0.91, 1.68) 0.17
ICU admission 4.5 (1.6, 7.3) 4.1 (2.6, 5.7) 0.4 (−2.9, 3.6) 0.83 1.09 (0.52, 2.28) 0.83
Mechanical ventilation 4.0 (1.3, 6.7) 3.5 (2.1, 4.9) 0.5 (−2.6, 3.6) 0.75 1.14 (0.51, 2.52) 0.75
Renal replacement therapy 1.0 (−0.4, 2.4) 1.2 (0.3, 2.2) −0.2 (−1.9, 1.4) 0.77 0.80 (0.16, 3.90) 0.78
History of cardiovascular disease Death 21.7 (4.5, 39.0) 29.7 (19.0, 40.4) −7.9 (−28.0, 12.1) 0.44 0.73 (0.31, 1.73) 0.48
Hospitalization 31.3 (7.8, 54.7) 42.4 (29.2, 55.7) −11.2 (−37.6, 15.2) 0.41 0.74 (0.33, 1.63) 0.45
ICU admission 9.1 (−3.2, 21.4) 10.2 (3.8, 16.7) −1.1 (−14.8, 12.5) 0.87 0.89 (0.20, 3.86) 0.88
Mechanical ventilation 8.7 (−3.1, 20.5) 7.9 (2.2, 13.5) 0.8 (−12.1, 13.7) 0.90 1.11 (0.24, 5.02) 0.90
Renal replacement therapy 4.3 (−4.2, 12.9) 4.4 (0.1, 8.7) −0.1 (−9.5, 9.3) 0.98 0.98 (0.11, 8.44) 0.98
Not healthcare professional Death 7.0 (3.3, 10.7) 8.0 (5.7, 10.2) −0.9 (−5.3, 3.4) 0.67 0.88 (0.49, 1.60) 0.68
Hospitalization 27.9 (21.0, 34.7) 26.4 (22.5, 30.4) 1.4 (−6.5, 9.3) 0.72 1.05 (0.79, 1.41) 0.72
ICU admission 5.4 (2.2, 8.7) 6.1 (4.1, 8.1) −0.7 (−4.5, 3.1) 0.73 0.89 (0.45, 1.76) 0.73
Mechanical ventilation 4.9 (1.8, 8.0) 5.1 (3.2, 6.9) −0.2 (−3.8, 3.4) 0.92 0.96 (0.46, 2.00) 0.92
Renal replacement therapy 1.1 (−0.4, 2.6) 2.1 (0.8, 3.4) −1.0 (−3.0, 1.0) 0.32 0.52 (0.12, 2.37) 0.40
Open in a new tab

NSAID use was defined as a filled prescription within 30 days prior to the date of cohort entry.

ICU, intensive care unit; NSAID, non-steroidal anti-inflammatory drug.

Supplementary analyses with different outcome or exposure assessment windows

Increasing the duration of follow-up to 60 days for death and 30 days for hospitalization, ICU admission, mechanical ventilation, and acute renal replacement therapy did not influence the findings (S2 Table).

When extending the definition of current NSAID use to a filled prescription up to 60 days before the test date, we observed similar null findings (S3 Table). Likewise, defining exposure as a filled prescription 60 days to 14 days before the test date yielded comparable results (S4 Table).

Test-negative individuals

We identified 204,920 individuals with a negative SARS-CoV-2 PCR test in the study period. Of these, 3,506 were excluded due to migration within 1 year prior to cohort entry, resulting in a population of 201,414 individuals followed up for a total of 15,840 person-years. Use of NSAIDs was associated with a decreased risk of death (RR 0.64, 95% CI 0.49 to 0.84, p < 0.01) and increased risk of hospitalization (RR 1.18, 95% CI 1.08 to 1.28, p < 0.001) and ICU admission (RR 1.39, 95% CI 1.00–1.95, p = 0.05) in the adjusted analyses (Table 4).

Table 4. Association between current NSAID use and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy in unmatched and propensity-score-matched cohorts of individuals who tested negative for SARS-CoV-2.

Outcome NSAID users Non-users Comparison
Number of events/sample size Risk (%) (95% CI) Number of events/sample size Risk (%) (95% CI) Risk difference (%) (95% CI) p-Value Risk ratio (95% CI) p-Value
Unmatched cohort
Death 78/5,574 1.4 (1.1, 1.7) 2,830/195,840 1.4 (1.4, 1.5) −0.0 (−0.4, 0.3) 0.77 0.97 (0.77, 1.21) 0.078
Hospitalization* 757/5,091 14.9 (13.9, 15.8) 18,543/186,479 9.9 (9.8, 10.1) 4.9 (3.9, 5.9) <0.001 1.50 (1.40, 1.60) <0.001
ICU admission* 63/5,547 1.1 (0.9, 1.4) 1,247/195,332 0.6 (0.6, 0.7) 0.5 (0.2, 0.8) <0.01 1.78 (1.38, 2.29) <0.001
Mechanical ventilation* 38/5,558 0.7 (0.5, 0.9) 698/195,582 0.4 (0.3, 0.4) 0.3 (0.1, 0.5) <0.01 1.92 (1.38, 2.65) <0.001
Renal replacement therapy* 7/5,573 0.1 (0.0, 0.2) 166/195,754 0.1 (0.1, 0.1) 0.0 (−0.1, 0.1) 0.39 1.48 (0.70, 3.15) 0.31
Matched cohort
Death 61/5,018 1.2 (0.9, 1.5) 382/20,072 1.9 (1.7, 2.1) −0.7 (−1.1, −0.3) <0.001 0.64 (0.49, 0.84) <0.01
Hospitalization* 651/4,613 14.1 (13.1, 15.1) 2,261/18,892 12.0 (11.4, 12.5) 2.1 (1.0, 3.3) <0.001 1.18 (1.08, 1.28) <0.001
ICU admission* 50/4,992 1.0 (0.7, 1.3) 144/20,024 0.7 (0.6, 0.9) 0.3 (−0.0, 0.6) 0.07 1.39 (1.00, 1.95) 0.05
Mechanical ventilation* 29/5,003 0.6 (0.4, 0.8) 95/20,050 0.5 (0.4, 0.6) 0.1 (−0.1, 0.3) 0.38 1.22 (0.79, 1.89) 0.36
Renal replacement therapy* 6/5,017 0.1 (0.0, 0.2) 16/20,060 0.1 (0.0, 0.1) 0.0 (−0.1, 0.1) 0.45 1.50 (0.58, 3.89) 0.41
Open in a new tab

NSAID use was defined as a filled prescription within 30 days prior to the date of cohort entry.

*Patients with a secondary outcome occurring during the exclusion assessment window were excluded, resulting in exclusion of n = 9,844 patients for hospitalization, n = 535 for ICU admission, n = 274 for mechanical ventilation, and n = 87 for renal replacement therapy in unmatched cohorts, and n = 1,585, 74, 37, and 13, respectively, in matched cohorts.

ICU, intensive care unit; NSAID, non-steroidal anti-inflammatory drug; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Discussion

We examined whether use of NSAIDs was associated with 30-day mortality and adverse outcomes in a nationwide population of SARS-CoV-2-positive individuals. Use of NSAIDs was not associated with increased 30-day mortality, a finding that was robust in a range of supplementary analyses. Likewise, use of NSAIDs was not associated with an increased risk of hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in the adjusted analyses.

Strengths and limitations

The Danish nationwide registries allowed for identification of all individuals who had been tested for SARS-CoV-2 in Denmark and allowed for obtaining data on prescription drug use, medical history, migration, hospital admissions, and death through individual-level linkage between health and administrative registries. Thus, we were able to include SARS-CoV-2-positive individuals managed in the community, unlike other data sources that mainly record hospitalized patients. Further, the SARS-CoV-2 test-negative population allowed us to conduct a negative control analysis.

The main limitations of our study are potential misclassification of non-users as NSAID users; potentially unmeasured confounding due to a lack of information on study participants’ bodyweight, an important risk factor of severe COVID-19; and confounding by indication due to NSAIDs possibly being prescribed due to early symptoms of severe COVID-19.

In Denmark, NSAIDs can only be obtained via prescription, except for low-dose (200 mg) ibuprofen. With the limited availability and use of NSAIDs over-the-counter in Denmark, misclassification from over-the-counter purchases of NSAIDs is of less concern [19]. However, exposure misclassification may still be present since information on adherence, intended duration, and dose was not available. Some patients do not use NSAIDs continuously after filling a prescription, and consequently some of these patients will have been incorrectly classified as NSAID users at the time of the positive test for SARS-CoV-2. The fact that a patient had filled a prescription for an NSAID may be considered an indicator of availability of NSAIDs rather than of actual use of NSAIDs. As information on exposure status was collected prior to our outcomes of interest, the misclassification is nondifferential and may introduce a bias towards the null. This could lead to wrongly dismissing a causal detrimental effect of NSAIDs on the prognosis of COVID-19 if many NSAID users truly were non-users.

The time of cohort entry was defined by the SARS-CoV-2 test date because information on time of symptom onset was not available. Thus, the timing of NSAID use relative to cohort entry will not necessarily reflect NSAID use in the early course of COVID-19 disease.

Users of NSAIDs were more likely to be overweight or obese than non-users, both among individuals who tested positive for SARS-CoV-2 and those who tested negative. This is possibly explained by the fact that a diagnosis of overweight or obesity in the Danish National Patient Registry is dependent on a hospital admission or outpatient clinic visit. This is also a likely explanation for the relatively low prevalence of overweight or obesity in this study. The positive predictive value of these diagnoses in the registries is, however, high [28].

Use of NSAIDs has been associated with lower mortality among elderly individuals, presumably because of confounding by indication [29], i.e., NSAIDs are preferentially prescribed to younger, less frail patients because of the established renal, gastrointestinal, and cardiovascular adverse effects [30]. Considerable media attention to the hypothesized risks of use of NSAIDs in COVID-19 may also have influenced how physicians prescribed NSAIDs to selected patients. Finally, severe symptoms early in the course of COVID-19 disease, before the patient is known to be infected with SARS-CoV-2, may increase the likelihood of being prescribed NSAIDs, which would bias the effect estimates towards an increased risk of severe disease associated with NSAIDs.

The secondary outcomes reflecting in-hospital treatment decisions may be more prone to confounding by indication because of the clinical selection of patients to be hospitalized or admitted to the ICU. For example, besides disease severity, factors such as age, comorbidity, and expected outcomes are involved in the ICU triage decision.

Ideally, confounding by indication would be mitigated using an active comparator; however, a suitable active comparator does not exist for ibuprofen. In a previous study, users of paracetamol differed more from NSAID users than did non-users of NSAIDs [9].

Findings in relation to other studies

The lack of association between use of NSAIDs and adverse outcomes in individuals who tested positive for SARS-CoV-2 in our study could be explained by multiple factors. First, NSAIDs may not increase angiotensin converting enzyme 2 in humans. The original hypothesis stems from experiments conducted in diabetic rats [31], and the findings may not transfer between organisms. Second, increased angiotensin converting enzyme 2 expression may not affect the risk of severe COVID-19. Studies on angiotensin converting enzyme inhibitors and angiotensin receptor blockers and the risk of contracting COVID-19 or experiencing a severe course of disease have not shown any association [32–34]. Third, the adverse effects of NSAIDs on the course of pneumonia may be specific to bacterial infections. A recent study on the risk of adverse outcomes in users of NSAIDs hospitalized for influenza found no association between use of NSAIDs and ICU admission or death [9], similar to the findings in this study.

Considering the available evidence, there is no reason to withdraw well-indicated use of NSAIDs during the SARS-CoV-2 pandemic. However, the well-established adverse effects of NSAIDs, particularly their renal, gastrointestinal, and cardiovascular effects, should always be considered, and NSAIDs should be used in the lowest possible dose for the shortest possible duration for all patients [30].

Conclusions

Use of NSAIDs was not associated with an increased risk of 30-day mortality or adverse outcomes in patients infected with SARS-CoV-2 in this cohort of all Danish residents who tested positive for SARS-CoV-2.

Supporting information

S1 STROBE Checklist. STROBE checklist of items that should be included in reports of cohort studies.

(DOCX)

Click here for additional data file. (40.7KB, docx)
S1 Appendix. Detailed information on registries used in this study.

(DOCX)

Click here for additional data file. (13.6KB, docx)
S2 Appendix. Codes used to define exposure, outcome, and covariate variables.

(DOCX)

Click here for additional data file. (15.2KB, docx)
S1 Table. Univariate association with death (RRcd) and use of NSAIDs (RRce) for each covariate in the PS.

(DOCX)

Click here for additional data file. (15.4KB, docx)
S2 Table. Association between current NSAID use and mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy using an outcome assessment window of 60 days for mortality and 30 days for secondary outcomes.

(DOCX)

Click here for additional data file. (15.9KB, docx)
S3 Table. Association between use of NSAIDs within 60 days before cohort entry and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy.

(DOCX)

Click here for additional data file. (15.8KB, docx)
S4 Table. Association between NSAID prescription fills within the period 60 days to 14 days before cohort entry and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy.

(DOCX)

Click here for additional data file. (15.8KB, docx)

Acknowledgments

The departments of clinical microbiology throughout Denmark are acknowledged for contributing to the national infectious disease surveillance. The Danish Health Data Authority and Statens Serum Institut are acknowledged for valuable support with preparation and linkage of data.

Abbreviations

COVID-19

coronavirus disease 2019

ICU

intensive care unit

NSAID

non-steroidal anti-inflammatory drug

PS

propensity score

RD

risk difference

RR

risk ratio

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

Data Availability

Due to data protection regulation, data cannot be shared directly by the authors. Data is accessible to authorized researchers after application to the Danish Health Data Authority. To apply for data and help with the application process, please see https://sundhedsdatastyrelsen.dk/da/forskerservice/ansog-om-data.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21 10.1016/S2213-2600(20)30116-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086 10.1136/bmj.m1086 [DOI] [PubMed] [Google Scholar]
  • 3.European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. EMA/136850/2020. Amsterdam: European Medicines Agency; 2020 [cited 2020 Aug 3]. Available from: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19.
  • 4.Basille D, Thomsen RW, Madsen M, Duhaut P, Andrejak C, Jounieaux V, et al. Nonsteroidal antiinflammatory drug use and clinical outcomes of community-acquired pneumonia. Am J Respir Crit Care Med. 2018;198:128–31. 10.1164/rccm.201802-0229LE [DOI] [PubMed] [Google Scholar]
  • 5.Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019;8:786 10.3390/jcm8060786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Meganathan P, Awasthi S. Predicting complicated parapneumonic effusion in community acquired pneumonia: hospital based case-control study. Indian J Pediatr. 2019;86:140–7. 10.1007/s12098-018-2769-y [DOI] [PubMed] [Google Scholar]
  • 7.Messika J, Sztrymf B, Bertrand F, Billard-Pomares T, Barnaud G, Branger C, et al. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care. 2014;29:733–8. 10.1016/j.jcrc.2014.05.021 [DOI] [PubMed] [Google Scholar]
  • 8.Epperly H, Vaughn FL, Mosholder AD, Maloney EM, Rubinson L. Nonsteroidal anti-inflammatory drug and aspirin use, and mortality among critically ill pandemic H1N1 influenza patients: an exploratory analysis. Jpn J Infect Dis. 2016;69:248–51. 10.7883/yoken.JJID.2014.577 [DOI] [PubMed] [Google Scholar]
  • 9.Lund LC, Reilev M, Hallas J, Kristensen KB, Thomsen RW, Christiansen CF, et al. Association of nonsteroidal anti-inflammatory drug use and adverse outcomes among patients hospitalized with influenza. JAMA Netw Open. 2020;3:e2013880 10.1001/jamanetworkopen.2020.13880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Use of non-steroidal anti-inflammatory drugs and clinical outcome of COVID-19: a Danish nationwide cohort study. EUPAS34734. Amsterdam: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance; 2020 [cited 2020 Aug 3]. Available from: http://www.encepp.eu/encepp/viewResource.htm?id=34735.
  • 11.Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39:12–6. 10.1177/1403494811399956 [DOI] [PubMed] [Google Scholar]
  • 12.Pottegård A, Kristensen KB, Reilev M, Lund LC, Ernst MT, Hallas J, et al. Existing data sources in clinical epidemiology: the Danish COVID-19 cohort. Clin Epidemiol. In press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Voldstedlund M, Haarh M, Mølbak K, MiBa Board of Representatives. The Danish Microbiology Database (MiBa) 2010 to 2013. Euro Surveill. 2014;19:20667 10.2807/1560-7917.es2014.19.1.20667 [DOI] [PubMed] [Google Scholar]
  • 14.Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–91. 10.2147/CLEP.S179083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798–798f. 10.1093/ije/dyw213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90. 10.2147/CLEP.S91125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39:26–9. 10.1177/1403494811399958 [DOI] [PubMed] [Google Scholar]
  • 18.Blichert-Hansen L, Nielsson MS, Nielsen RB, Christiansen CF, Nørgaard M. Validity of the coding for intensive care admission, mechanical ventilation, and acute dialysis in the Danish National Patient Registry: a short report. Clin Epidemiol. 2013;5:9–12. 10.2147/CLEP.S37763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol. 2014;6:155–68. 10.2147/CLEP.S59156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Schmidt M, Hallas J, Laursen M, Friis S. Data resource profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401–1402g. 10.1093/ije/dyw116 [DOI] [PubMed] [Google Scholar]
  • 21.Kristensen KB, Karlstad Ø, Martikainen JE, Pottegård A, Wastesson JW, Zoega H, et al. Nonaspirin nonsteroidal antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: a drug utilization study. Pharmacotherapy. 2019;39:150–60. 10.1002/phar.2217 [DOI] [PubMed] [Google Scholar]
  • 22.Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55. 10.1093/biomet/70.1.41 [DOI] [Google Scholar]
  • 23.Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol. 2010;172:843–54. 10.1093/aje/kwq198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Boston: Boston College Department of Economics; 2018. [cited 2020 Aug 3]. Available from: https://ideas.repec.org/c/boc/bocode/s432001.html. [Google Scholar]
  • 25.Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020. May 5 10.1002/pds.5029 [DOI] [PubMed] [Google Scholar]
  • 26.Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects: metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33:1685–99. 10.1002/sim.6058 [DOI] [PubMed] [Google Scholar]
  • 27.Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21:697–709. 10.1002/pds.2256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gribsholt SB, Pedersen L, Richelsen B, Thomsen RW. Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals. Clin Epidemiol. 2019;11:845–54. 10.2147/CLEP.S214909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiol. 2001;12:682–9. 10.1097/00001648-200111000-00017 [DOI] [PubMed] [Google Scholar]
  • 30.Schmidt M, Lamberts M, Olsen A-MS, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2016;2:108–18. 10.1093/ehjcvp/pvv054 [DOI] [PubMed] [Google Scholar]
  • 31.Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131:97–106. 10.1159/000375362 [DOI] [PubMed] [Google Scholar]
  • 32.Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. May 5 10.1001/jamacardio.2020.1855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–40. 10.1056/NEJMoa2006923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–8. 10.1056/NEJMoa2008975 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Artur Arikainen

16 Jun 2020

Dear Dr Pottegaard,

Thank you for submitting your manuscript entitled "Adverse Outcomes and Mortality in Users of Non-Steroidal Anti-Inflammatory Drugs tested positive for SARS-CoV-2: A Danish Nationwide Cohort Study" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by .

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Artur Arikainen,

Associate Editor

PLOS Medicine

Decision Letter 1

Emma Veitch

30 Jun 2020

Dear Dr. Pottegaard,

Thank you very much for submitting your manuscript "Adverse Outcomes and Mortality in Users of Non-Steroidal Anti-Inflammatory Drugs tested positive for SARS-CoV-2: A Danish Nationwide Cohort Study" (PMEDICINE-D-20-02753R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Jul 21 2020 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Emma Veitch, PhD

PLOS Medicine

On behalf of Clare Stone, PhD, Acting Chief Editor,

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

*In the last sentence of the Abstract Methods and Findings section, please include a brief note regarding any key limitation(s) of the study methods overall.

*At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

*As noted by one reviewer, it would be good to include in the Discussion a more explicit and thorough discussion of the main limitations of the study methods to answer the question of interest.

*As the paper reports analyses of data from a cohort study, it would be good to ensure that the study is reported according to the STROBE guideline; if doing this please include the completed STROBE checklist as Supporting Information. Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (SChecklist)." The STROBE guideline can be found here: http://www.equator-network.org/reporting-guidelines/strobe/. When completing the checklist, please use section and paragraph numbers, rather than page numbers.

-----------------------------------------------------------

Comments from the reviewers:

Reviewer #1: I greatly enjoyed reading this manuscript, which is very neatly written with the entire emphasis on solid statistical evaluation, as I would expect. Some of the English is cumbersome and sloppy (eg. abstract: "matched to up to...") but on the whole it is an excellent paper, and a useful addition to the literature.

Considering the methods used and the 'solidity' of the database I have some suggestions, and I am deliberately keeping this brief:

1. It would be helpful if statins could be studied too, using almost identical methods. The title would need to be changed to reflect this.

2. In view of the RECOVERY data on dexamethasone, can steroids be looked at too? These data should at least be mentioned. As per 1.

3. It was disappointing not to see a paragraph or 2, in the introduction and discussion, on mechanisms here that may be relevant and operational, leading the authors to study this as more than a simple correlation ie. is there any suggestion that the potential association may have been causative and problematic, based on the first line of the abstract? This is not expanded upon anywhere in the text and I do not see clinicians concerned any more about NSAID use (this is an old story as the authors know).

4. There is no substantial limitations paragraph with the usual dose, duration etc discussion.

J Stebbing

-----------------------------------------------------------

Reviewer #2: I confine my remarks to statistical aspects of this paper. These were very well done and I recommend publication.

Peter Flom

-----------------------------------------------------------

Reviewer #3: This is an interesting and relevant observational study to estimate if there is any effect on patients who obtained a prescription for NSAIDs 30 days prior to a positive SARS-CoV-2 PCR test on mortality within 30 days (primary outcome) or hospitalisation, ICU admission, ventilation or acute renal replacement therapy within 14 days. This has been the subject of much debate during the current COVID-19 outbreak so represents a valuable contribution to the field and will likely impact on clinical management or public health policy.

The set of baseline covariates were defined (age, gender, comorbidities, use of other selected medications plus phase of the outbreak) and the methodology is appropriate. Propensity scores were used to ensure that the 'treated' subjects are similar in their baseline covariates to 'untreated' subjects (matched 1: 4 in this case) in order to provide an unbiased estimate of the relative risk of NSAIDs on the measured outcomes. Additional stratification looked at age (<65y; >65y), gender, cardiovascular disease and non-healthcare worker.

The analyses do not indicate that NSAIDs presented an increased risk of mortality or morbidity in the COVID-19 population in Denmark.

-----------------------------------------------------------

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Artur Arikainen

9 Jul 2020

Dear Dr. Pottegaard,

Thank you very much for re-submitting your manuscript "Adverse Outcomes and Mortality in Users of Non-Steroidal Anti-Inflammatory Drugs tested positive for SARS-CoV-2: A Danish Nationwide Cohort Study" (PMEDICINE-D-20-02753R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 1 reviewer. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

Our publications team (plosmedicine@plos.org) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU'VE RECEIVED THE PRODUCTION REQUIREMENTS.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.

We look forward to receiving the revised manuscript by Jul 16 2020 11:59PM.

Sincerely,

Artur Arikainen,

Associate Editor

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

1. When completing the STROBE checklist, please use section and paragraph numbers, rather than page numbers.

2. The Data Availability Statement (DAS) requires revision. If the data are owned by a third party, please provide contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data.

3. Abstract:

a. Line 35: please correct to: “…use of NSAIDs was…”

b. Line 48: please include basic cohort demographics (age and sex).

c. Please quantify all results with both 95% CIs and p values.

d. Line 53 (and throughout the text): please correct to: “…ICU admission…” (no hyphen)

4. Author Summary:

a. Line 71: please spell out NSAIDs.

5. Results:

a. Please quantify all results in the text and tables with both 95% CIs and p values.

b. Lines 232-233: Please give absolute numbers as well as percentages.

6. All tables and figure: Please define all abbreviations (eg. RT-PCR, IQR, SMD, COPD, ICU, NSAIDs) in the legend or footnote.

7. Lines 397-418: Please remove these sections on Funding, Competing Interests, and Author Contributions, and ensure the information is instead filled in on the submission form.

8. Lines 420-424: Please move details on ethical approval to the Methods section.

9. Re: reference 30 listed as under review, papers cannot be listed in the reference list until they have been accepted for publication or are otherwise publically accessible (for example, in a preprint archive). The information may be cited in the text as a personal communication with the author if the author provides written permission to be named. Alternatively, please provide a different appropriate reference.

-----

Comments from Reviewers:

Reviewer #1: excellent answers, lovely paper, congratulations, justin stebbing

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Artur Arikainen

3 Aug 2020

Dear Dr Pottegaard,

On behalf of my colleagues and the academic editor, Dr. Anne C Cunningham, I am delighted to inform you that your manuscript entitled "Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs tested positive for SARS-CoV-2: A Danish nationwide cohort study" (PMEDICINE-D-20-02753R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer's (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to https://www.editorialmanager.com/pmedicine, log in, and click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Artur Arikainen,

Associate Editor

PLOS Medicine

plosmedicine.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 STROBE Checklist. STROBE checklist of items that should be included in reports of cohort studies.

    (DOCX)

    Click here for additional data file. (40.7KB, docx)
    S1 Appendix. Detailed information on registries used in this study.

    (DOCX)

    Click here for additional data file. (13.6KB, docx)
    S2 Appendix. Codes used to define exposure, outcome, and covariate variables.

    (DOCX)

    Click here for additional data file. (15.2KB, docx)
    S1 Table. Univariate association with death (RRcd) and use of NSAIDs (RRce) for each covariate in the PS.

    (DOCX)

    Click here for additional data file. (15.4KB, docx)
    S2 Table. Association between current NSAID use and mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy using an outcome assessment window of 60 days for mortality and 30 days for secondary outcomes.

    (DOCX)

    Click here for additional data file. (15.9KB, docx)
    S3 Table. Association between use of NSAIDs within 60 days before cohort entry and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy.

    (DOCX)

    Click here for additional data file. (15.8KB, docx)
    S4 Table. Association between NSAID prescription fills within the period 60 days to 14 days before cohort entry and 30-day mortality, hospitalization, ICU admission, mechanical ventilation, and renal replacement therapy.

    (DOCX)

    Click here for additional data file. (15.8KB, docx)
    Attachment

    Submitted filename: response-reviewer-comments-v4.docx

    Click here for additional data file. (27.2KB, docx)

    Data Availability Statement

    Due to data protection regulation, data cannot be shared directly by the authors. Data is accessible to authorized researchers after application to the Danish Health Data Authority. To apply for data and help with the application process, please see https://sundhedsdatastyrelsen.dk/da/forskerservice/ansog-om-data.

    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES